Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes

RF Bruns and JH Fergus

Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105.

Several 2-amino-3-benzoylthiophenes were found to increase the binding of [3H]N6-cyclohexyladenosine to A1 adenosine receptors in rat brain membranes. Concentration-response curves were bell-shaped, with up to 45% stimulation of binding at 10 microM followed by inhibition at higher concentrations. Because these compounds originated from a series of nonxanthine adenosine antagonists, the inhibition of binding was attributed to the presence of interfering adenosine antagonist activity. The compounds stimulated binding of several A1 agonist ligands but only inhibited binding of the A1 antagonist ligand [3H]8- cyclopentyl-1,3-dipropylxanthine, indicating that enhancement was specific for the agonist conformation of the receptor. The enhancement was also specific for the A1 receptor, because agonist binding to A2 adenosine, M2 muscarinic, alpha 2 adrenergic, and delta opiate receptors showed little or no enhancement. Uncoupling of the A1 receptor from the inhibitory guanine nucleotide-binding protein did not prevent enhancement. The enhancers slowed the dissociation of [3H]N6- cyclohexyladenosine from the A1 receptor, implying an allosteric mechanism of action. The inhibition of forskolin-stimulated cyclic AMP accumulation in FRTL-5 cells was employed as a functional index of A1 receptor activation. The enhancers caused up to 19-fold leftward shifts in the concentration-response curve for N6-cyclopentyladenosine and also caused up to 55% inhibition of cyclic AMP accumulation in the absence of agonist. The binding and functional results are consistent with a model in which the enhancers bind preferentially to the agonist conformation of the A1 receptor, thereby shifting the receptor equilibrium in favor of agonist binding. Adenosine enhancers may be useful for ischemia and other conditions involving local energy deficits. More generally, allosteric enhancers may provide a means for strengthening physiological control circuits in a variety of receptor systems.

Volume 38, Issue 6, pp. 939-949, 12/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. H. Heitman, K. Ye, J. Oosterom, and A. P. IJzerman Amiloride Derivatives and a Nonpeptidic Antagonist Bind at Two Distinct Allosteric Sites in the Human Gonadotropin-Releasing Hormone Receptor Mol. Pharmacol., June 1, 2008; 73(6): 1808 - 1815. [Abstract] [Full Text] [PDF]

				S. R. J. Hoare, B. A. Fleck, R. S. Gross, P. D. Crowe, J. P. Williams, and D. E. Grigoriadis Allosteric Ligands for the Corticotropin Releasing Factor Type 1 Receptor Modulate Conformational States Involved in Receptor Activation Mol. Pharmacol., May 1, 2008; 73(5): 1371 - 1380. [Abstract] [Full Text] [PDF]

				B. Holst, E. Brandt, A. Bach, A. Heding, and T. W. Schwartz Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling Mol. Endocrinol., September 1, 2005; 19(9): 2400 - 2411. [Abstract] [Full Text] [PDF]

				V. Avlani, L. T. May, P. M. Sexton, and A. Christopoulos Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1062 - 1072. [Abstract] [Full Text] [PDF]

				H. Figler, R. A. Olsson, and J. Linden Allosteric Enhancers of A1 Adenosine Receptors Increase Receptor-G Protein Coupling and Counteract Guanine Nucleotide Effects on Agonist Binding Mol. Pharmacol., December 1, 2003; 64(6): 1557 - 1564. [Abstract] [Full Text] [PDF]

				X. Li, D. Conklin, H.-L. Pan, and J. C. Eisenach Allosteric Adenosine Receptor Modulation Reduces Hypersensitivity Following Peripheral Inflammation by a Central Mechanism J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 950 - 955. [Abstract] [Full Text] [PDF]

				Z.-G. Gao, S.-K. Kim, A. S. Gross, A. Chen, J. B. Blaustein, and K. A. Jacobson Identification of Essential Residues Involved in the Allosteric Modulation of the Human A3 Adenosine Receptor Mol. Pharmacol., May 1, 2003; 63(5): 1021 - 1031. [Abstract] [Full Text] [PDF]

				Z.-G. Gao, S. G. Kim, K. A. Soltysiak, N. Melman, A. P. IJzerman, and K. A. Jacobson Selective Allosteric Enhancement of Agonist Binding and Function at Human A3 Adenosine Receptors by a Series of Imidazoquinoline Derivatives Mol. Pharmacol., July 1, 2002; 62(1): 81 - 89. [Abstract] [Full Text] [PDF]

				A. Christopoulos and T. Kenakin G Protein-Coupled Receptor Allosterism and Complexing Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374. [Abstract] [Full Text] [PDF]

				K. Zahn, N. Eckstein, C. Trankle, W. Sadee, and K. Mohr Allosteric Modulation of Muscarinic Receptor Signaling: Alcuronium-Induced Conversion of Pilocarpine from an Agonist into an Antagonist J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 720 - 728. [Abstract] [Full Text] [PDF]

				B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K.-N. Klotz, and J. Linden International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors Pharmacol. Rev., December 1, 2001; 53(4): 527 - 552. [Abstract] [Full Text] [PDF]

				Z.-G. Gao, J. E. Van Muijlwijk-Koezen, A. Chen, C. E. Muller, A. P. Ijzerman, and K. A. Jacobson Allosteric Modulation of A3 Adenosine Receptors by a Series of 3-(2-Pyridinyl)isoquinoline Derivatives Mol. Pharmacol., November 1, 2001; 60(5): 1057 - 1063. [Abstract] [Full Text]

				D. A. Hall Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor Activation Mol. Pharmacol., April 13, 2001; 58(6): 1412 - 1423. [Abstract] [Full Text]

				J. Ellis and M. Seidenberg Interactions of Alcuronium, TMB-8, and Other Allosteric Ligands with Muscarinic Acetylcholine Receptors: Studies with Chimeric Receptors Mol. Pharmacol., April 13, 2001; 58(6): 1451 - 1460. [Abstract] [Full Text]

				V. Blandin, P. Vigne, J. P. Breittmayer, and C. Frelin Allosteric Inhibition of Endothelin ETA Receptors by 3,5-Dibromosalicylic Acid Mol. Pharmacol., April 13, 2001; 58(6): 1461 - 1469. [Abstract] [Full Text]

				L. Wu, L. Belardinelli, J. A. Zablocki, V. Palle, and J. C. Shryock A partial agonist of the A1-adenosine receptor selectively slows AV conduction in guinea pig hearts Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H334 - H343. [Abstract] [Full Text] [PDF]

				R. A. Leppik and N. J. M. Birdsall Agonist Binding and Function at the Human alpha 2A-Adrenoceptor: Allosteric Modulation by Amilorides Mol. Pharmacol., November 1, 2000; 58(5): 1091 - 1099. [Abstract] [Full Text]

				A. Talbodec, N. Berkane, V. Blandin, J. P. Breittmayer, E. Ferrari, C. Frelin, and P. Vigne Aspirin and Sodium Salicylate Inhibit Endothelin ETA Receptors by an Allosteric Type of Mechanism Mol. Pharmacol., April 1, 2000; 57(4): 797 - 804. [Abstract] [Full Text]

				C. Tränkle, O. Weyand, A. Schröter, and K. Mohr Using a Radioalloster to Test Predictions of the Cooperativity Model for Gallamine Binding to the Allosteric Site of Muscarinic Acetylcholine M2 Receptors Mol. Pharmacol., November 1, 1999; 56(5): 962 - 965. [Abstract] [Full Text]

				N. J. M. Birdsall, T. Farries, P. Gharagozloo, S. Kobayashi, S. Lazareno, and M. Sugimoto Subtype-Selective Positive Cooperative Interactions Between Brucine Analogs and Acetylcholine at Muscarinic Receptors: Functional Studies Mol. Pharmacol., April 1, 1999; 55(4): 778 - 786. [Abstract] [Full Text]

				B. Musser, R. V. Mudumbi, J. Liu, R. D. Olson, and R. E. Vestal Adenosine A1 Receptor-Dependent and -Independent Effects of the Allosteric Enhancer PD 81,723 J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 446 - 454. [Abstract] [Full Text]

				C. Tränkle, E. Mies-Klomfass, M. H. B. Cid, U. Holzgrabe, and K. Mohr Identification of a [3H]Ligand for the Common Allosteric Site of Muscarinic Acetylcholine M2 Receptors Mol. Pharmacol., July 1, 1998; 54(1): 139 - 145. [Abstract] [Full Text]

				J. C. Shryock, M. J. Ozeck, and L. Belardinelli Inverse Agonists and Neutral Antagonists of Recombinant Human A1 Adenosine Receptors Stably Expressed in Chinese Hamster Ovary Cells Mol. Pharmacol., May 1, 1998; 53(5): 886 - 893. [Abstract] [Full Text]

				C. A. Kollias-Baker, J. Ruble, M. Jacobson, J. K. Harrison, M. Ozeck, J. C. Shryock, and L. Belardinelli Agonist-Independent Effect of an Allosteric Enhancer of the A1 Adenosine Receptor in CHO Cells Stably Expressing the Recombinant Human A1 Receptor J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 761 - 768. [Abstract] [Full Text]

				T. Mizumura, J. A. Auchampach, J. Linden, R. F. Bruns, and G. J. Gross PD 81,723, an Allosteric Enhancer of the A1 Adenosine Receptor, Lowers the Threshold for Ischemic Preconditioning in Dogs Circ. Res., September 1, 1996; 79(3): 415 - 423. [Abstract] [Full Text]